Regulation of Osteoblast Differentiation by Cytokine Networks

Dulshara Sachini Amarasekara 1, Sumi Kim 2,† and Jaerang Rho 2,*,†

1 Department of Zoology and Environment Sciences, Faculty of Science, University of Colombo, Colombo 0300, Sri Lanka; sachini@zoology.cmb.ac.lk
2 Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 34134, Korea; na12423@naver.com
* Correspondence: jrrho@cnu.ac.kr; Tel.: +82-42-821-6420; Fax: +82-42-822-7367

Abstract: Osteoblasts, which are bone-forming cells, play pivotal roles in bone modeling and remodeling. Osteoblast differentiation, also known as osteoblastogenesis, is orchestrated by transcription factors, such as runt-related transcription factor 1/2, osterix, activating transcription factor 4, special AT-rich sequence-binding protein 2 and activator protein-1. Osteoblastogenesis is regulated by a network of cytokines under physiological and pathophysiological conditions. Osteoblastogenic cytokines, such as interleukin-10 (IL-10), IL-11, IL-18, interferon-γ (IFN-γ), cardiotrophin-1 and oncostatin M, promote osteoblastogenesis, whereas anti-osteoblastogenic cytokines, such as tumor necrosis factor-α (TNF-α), TNF-β, IL-1α, IL-4, IL-7, IL-12, IL-13, IFN-α, IFN-β, leukemia inhibitory factor, cardiotrophin-like cytokine, and ciliary neurotrophic factor, downregulate osteoblastogenesis. Although there are gaps in the body of knowledge regarding the interplay of cytokine networks in osteoblastogenesis, cytokines appear to be potential therapeutic targets in bone-related diseases. Thus, in this study, we review and discuss our osteoblast, osteoblast differentiation, osteoblastogenesis, cytokines, signaling pathway of cytokine networks in osteoblastogenesis.

Keywords: osteoblast; osteoblast differentiation; osteoblastogenesis; cytokine; signaling pathway

1. Background

Bone modeling initially occurs during development, where there are two modes of bone development: intramembranous ossification and endochondral ossification [1]. In intramembranous ossification, mesenchymal tissues are directly converted to bone, while in endochondral ossification, mesenchymal tissues are differentiated into cartilage before being replaced by bone [1]. Bone remodeling is a life-long process in which the volume of bone resorbed by osteoclasts (OCs) is restored by bone-forming osteoblasts (OBs) [2]. A balance between OC and OB activity is crucial in maintaining physiological bone turnover rates, and a flaw in this balance can lead to debilitating bone diseases, such as rheumatoid arthritis (RA), periodontal diseases, and osteoporosis [3]. Thus, maintaining the biomechanical integrity of bone by either modeling or remodeling is a complex process regulated by numerous cell lineages, transcription regulation, a network of cytokines, and growth factors [2,4]. Adequate understanding of the regulation of OC and OB activity in bone tissue is crucial for the development of novel therapeutics to manage bone-related diseases. We have previously reviewed the role played by cytokines in regulating OC differentiation, also known as osteoclastogenesis, under physiological and pathophysiological conditions [2,5]. In this article, we review the current knowledge of the impact of cytokines in OB differentiation, also known as osteoblastogenesis.

2. OB Differentiation and Function

OBs, which are bone-forming cells, are small mononucleated cells of mesenchymal stem cell (MSC) origin [4]. OBs are usually cuboid in shape but can be found in morphologically diverse round, flat and cylindrical forms [5]. The sequential action of cytokine...
networks and transcription factors results in the differentiation of OB lineage cells from mesenchymal precursors (Figure 1) [4].

![Schematic representation of osteoblast (OB) differentiation.](image)

**Figure 1.** Schematic representation of osteoblast (OB) differentiation. MSC, mesenchymal stem cell. BMP, bone morphogenetic protein. FGF, fibroblast growth factor. RUNX2, runt-related transcription factor 2. PTH, parathyroid hormone. TGF, transforming growth factor. Hh, hedgehog. SATB2, special AT-rich sequence-binding protein 2. OSX, osterix. ATF4, activating transcription factor 4. CREB, cAMP-responsive element-binding. ALP, alkaline phosphatase. OPN, osteopontin. OCN, osteocalcin. ONN, osteonectin. BSP, bone sialoprotein. COL1A1, collagen type 1 alpha 1 chain.

OB lineage progenitor cells undergo three developmental stages: (1) cell proliferation, (2) extracellular matrix (ECM) secretion and matrix maturation and (3) matrix mineralization [6]. Following OB lineage commitment, pre-OBs undergo active proliferation and express collagen, fibronectin, osteopontin (OPN) and transforming growth factor-β (TGF-β) receptor 1 [7–9]. In the second stage, cell proliferation is downregulated, and immature OBs differentiate into mature OBs that secrete collagen type 1 alpha 1 chain (COL1A1) as the major constituent of the ECM and express alkaline phosphatase (ALP) to mature the ECM [7–9]. Upon completion of matrix maturation, matrix mineralization occurs in a highly ordered process via the expression of various osteoblastogenic markers, such as OPN, osteocalcin (OCN), and bone sialoprotein (BSP), with continued expression of ALP and COL1A1 [4,7]. OCN regulates calcium metabolism and promotes the deposition of minerals in the ECM, OCN promotes bone formation and mineralization, and BSP promotes mineralization regulating hydroxyapatite crystal formation [10,11]. Finally, mature OBs undergo apoptosis, become bone-lining cells or progressively incorporate into the bone matrix as terminally differentiated osteocytes (OSs) [6].

OBs orchestrate the bone remodeling process by regulating bone-resorbing OC differentiation and function through the production of two essential cytokines: receptor activator of nuclear factor-kappa B (RANK) ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) [2]. The binding of RANKL and M-CSF to receptors RANK and c-fms, respectively, on the surface of OC progenitors, induces a number of downstream signaling cascades, ultimately activating nuclear factor of activated T cells c1, a master transcription factor of osteoclastogenesis, leading to enhanced OC differentiation, proliferation and survival [2]. Moreover, OBs secrete osteoprotegerin (OPG), a key negative regulator of osteoclastogenesis that binds with RANKL, thereby hindering RANKL-RANK interaction [2]. Therefore, OBs are vital for maintaining balance in bone homeostasis by regulating the RANK/RANKL/OPG axis [2,12].

3. Transcriptional Regulation in Osteoblastogenesis

Osteoblastogenesis is regulated by multiple cytokines and hormone signaling cascades, resulting in subsequent activation of downstream transcription factors [13,14]. Among the downstream transcription factors, runt-related related transcription factor
 RUNX2/CBFA1/AML3/PEBP2αA) acts as the master transcription factor leading to the expression of osteoblastogenic markers, such as ALP, OCN, OPN, osteonectin (ONN), BSP, and COL1A1, in osteoblastogenesis [15–19]. Runx2-deficient mice exhibit defects in endochondral and intramembranous bone formation [16–18]. In osteoblastogenesis, RUNX2 is marginally expressed in uncommitted MSCs and elevated throughout the proliferation of pre-OBs [20,21]. RUNX2 level peaks at the immature OB stage and decreases in the maturation stage [20,21]. RUNX2 enhances the expression of osterix (OSX/Sp7), an essential transcription factor for OB commitment and differentiation [22,23]. OSX can induce the expression of ALP, OCN, OPN, ONN, BSP, and COL1A1 [24]. Osx-deficient mice also exhibit defects in bone formation due to the complete loss of OBs [22,25]. However, RUNX2 expression remains unaltered in Osx-deficient mice, demonstrating that RUNX2 is upstream of OSX in osteoblastogenesis [22,25]. The number of OB progenitors and their proliferation was lower in the calvariae of Runx2-deficient mice, whereas Osx-deficient mice had OB progenitors in abundance with adequate proliferation, demonstrating that RUNX2 is required for the expansion of OB progenitors [25]. Consequently, the transcription factors RUNX2 and OSX are of high importance in osteoblastogenesis.

Activating transcription factor 4 (ATF4), belonging to the cAMP-responsive element-binding (CREB) protein family of transcription factors, is another crucial transcription factor in osteoblastogenesis [26,27]. ATF4 promotes osteoblastogenesis through direct interaction with RUNX2 to enhance OCN expression [28]. ATF4-deficient mice are reported to have severe osteoporosis, osteodysplasty, and altered bone mineralization with impaired terminal differentiation of OBs, probably due to reduced expression of COL1A1, OCN, and BSP [26]. Moreover, ATF4 can promote osteoblastogenesis indirectly by modulating β-catenin levels in MSCs [29]. Thus, ATF4 expression is limited in committed OB lineage cells, whereas RUNX2 and OSX are more broadly expressed from OB lineage commitment to maturation during osteoblastogenesis (Figure 1) [27]. Taken together, ATF4 is a direct or indirect transcriptional regulator of osteoblastogenic marker expression in osteoblastogenesis.

A recent study implicated RUNX1 in promoting endochondral ossification and osteoblastogenesis [30,31]. RUNX1 is expressed at all stages in OB lineage cells [32]. In a conditional knockout study of Runx1<sup>flox/flox/Osx-Cre</sup> mice, RUNX1 deficiency resulted in decreased bone density by downregulating RUNX2, OSX, and ATF4 expression in OB lineage cells [30]. It was also determined that RUNX1 promotes RUNX2 and OCN expression by directly binding to the promoter regions of the RUNX2 and OCN genes [30]. Furthermore, RUNX1 can improve OB lineage commitment and promote bone formation by upregulating the bone morphogenetic protein-7 (BMP-7) and Wnt/β-catenin pathways [32]. Therefore, RUNX1 has emerged as a novel regulator of osteoblastogenesis.

A crucial role of activator protein-1 (AP-1) and special AT-rich sequence-binding protein 2 (SATB2) in OB differentiation and function is also evident from previous studies [33–35]. AP-1 is a dimeric transcription factor that is primarily composed of c-jun, c-fos, and ATF family dimers [33]. AP-1 activation is induced by stimulation of osteoblastogenic factors, such as parathyroid hormone (PTH), TGF-β and vitamin D, in osteoblastogenesis [33,34,36]. Deficiency of c-fos and ATF members in mice has highlighted their importance in OB differentiation and function [33]. Other AP-1 members, such as Fra-1, Fra-2, and ΔFosB (FosB2), are implicated in promoting OB differentiation and function [37]. SATB2 is also implicated in promoting OB differentiation and bone regeneration by inducing RUNX2/ATF4-mediated expression of osteoblastogenic markers, such as OCN and BSP [35,38]. In addition, SATB2-deficient mice exhibit defects in OB differentiation and function, leading to delayed bone formation and mineralization [35]. A recent study also demonstrated that SATB2 promotes OB progenitor proliferation [39].

4. Signaling Pathways in Osteoblastogenesis

Osteoblastogenesis is regulated by multiple signaling pathways, including Wnt, PTH, BMP, TGF-β, fibroblast growth factor (FGF), and hedgehog (Hh) (Figure 2) [40]. The Wnt signaling pathway plays a pivotal role in promoting OB differentiation, proliferation, and
4. Signaling Pathways in Osteoblastogenesis and maturation [40,41]. Wnt signaling can be categorized into two pathways: the canonical Wnt pathway and the non-canonical pathway [41]. The canonical Wnt pathway, also called the Wnt/β-catenin-dependent pathway, is best understood for its role in bone regeneration and repair [42]. In osteoblastogenesis, Wnt ligand binding to its receptors activates downstream signaling cascades, resulting in β-catenin translocation into the nucleus, thereby enhancing osteoblastogenic target gene expression (Figure 2) [4,43]. In the absence of Wnt ligand binding (or inactive state), β-catenin is phosphorylated by β-catenin destruction complex proteins, including axin, adenomatous polyposis coli, glycogen synthase kinase-3β, and casein kinase-1 [43]. Phosphorylated β-catenin is ubiquitinated by β-TRCP ubiquitin E3 ligase and degraded by the ubiquitin-dependent proteasomal system (Figure 2) [43]. Non-canonical Wnt signaling induced by Wnt5a or Wnt11 binding to a receptor complex consisting of frizzled and the receptor tyrosine kinase-like orphan receptor (ROR) coreceptor transduces signals through c-jun N-terminal kinase (JNK) activation to induce RUNX2 (Figure 2) [44]. Wnt5a-deficient mice had low OB numbers and reduced bone mass, indicating that Wnt5a is important for MSC lineage commitment to OB differentiation [45,46]. The Wnt/calcium pathway, one of the non-canonical Wnt signaling pathways, increases intracellular calcium levels to activate calmodulin-dependent kinase II, protein kinase C (PKC), and calcineurin, leading to the induction of AP-1 transcription factors (Figure 2) [47].

Figure 2. Key signaling pathways in osteoblastogenesis. BMP, bone morphogenetic protein. BMPR, BMP receptor. PTH, parathyroid hormone. PTH1R, PTH receptor 1. TGF-β, transforming growth factor-β. TGFβR, TGF-β receptor. FGF, fibroblast growth factor. FGFR, FGF receptor. Hh, hedgehog. PTCH1, patched 1. SMO, smoothened. RUNX1/2, runt-related transcription factor 1/2. OSX, osterix. ATF4, activating transcription factor 4. SATB2, special AT-rich sequence-binding protein 2. AP-1, activator protein-1. ROR, receptor tyrosine kinase-like orphan receptor. JNK, c-jun N-terminal kinase. CAMKII, calmodulin-dependent kinase II. PKC, protein kinase C. LRP, low-density lipoprotein receptor-related protein. APC, adenomatosis polyposis coli. CK1α, casein kinase 1α. GSK3β, glycogen synthase kinase 3β. cAMP, cyclic adenosine monophosphate. PKA, protein kinase A. CREB, cAMP-responsive element-binding. DLX5, distal-less homeobox 5. MAPK, mitogen-activated protein kinase. ERK, extracellular receptor kinase. PLC, phospholipase. AKT, protein kinase B. Gli, glioma-associated oncogene. Ub, Ubiquitin.
BMPs belong to the TGF-β superfamily and are reported to be osteoblastogenic factors [48]. In particular, it has been well-documented that BMP-2 is a potent inducer of osteoblastogenesis by activating the Smad signaling pathway [49,50]. BMPs bind to serine/threonine kinase receptor II and activate receptor I to transmit signals through Smad1/5/8 (Figure 2) [49–51]. Smad1/5/8 complexed with Smad4 is translocated to the nucleus to activate RUNX2, leading to enhanced expression of osteoblastogenic markers [49–51]. Moreover, treatment with antibodies against BMP-2, -4, and -7 can downregulate the expression of osteoblastogenic markers, such as ALP, OCN, and BSP, revealing that BMP-mediated signaling is crucial for RUNX2-mediated osteoblastogenesis [51]. BMP-2/Smad signaling is also reported to induce OSX through distal-less homeobox 5 (DLX5) induction in a RUNX2-independent manner [52]. In the cranial structure of the mesenchyme, DLX5 is reported to induce osteoblastogenesis by inducing RUNX2-mediated ALP and OPN expression, revealing that DLX5 is an upstream regulator of RUNX2 [53].

TGF-β can directly induce osteoblastogenesis from OB progenitor cells [54]. The ability of TGF-β to enhance OB proliferation, inhibit OB apoptosis, recruit OB precursors to the bone-forming site and produce ECM during osteoblastogenesis has been well-documented [55–58]. TGF-β binding to TGFβRI and TGFβRII triggers downstream signaling through Smad2/3 (Figure 2) [59]. Activated Smad2/3 forms a complex with Smad4 and undergoes nuclear translocation to induce RUNX2-mediated osteoblastogenic gene expression [59]. Moreover, TGF-β and BMPs can induce TGF-β activation kinase 1 to activate RUNX2 through the mitogen-activated protein kinase (MAPK) signaling pathway [59].

The FGF/FGF receptor (FGFR)-mediated signaling cascade regulates OB progenitor proliferation, maturation, and apoptosis [60]. FGF/FGFR signaling is reported to induce RUNX2 activation, leading to enhanced expression of osteoblastogenic markers, such as ALP, OCN, and COL1A1, through downstream signaling of phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT), phospholipase γ/PKCα and extracellular receptor kinase (ERK)1/2 (Figure 2) [60]. FGF2-deficient mice exhibit decreased bone mass and bone formation, and FGF18-deficient mice show delayed ossification [61–63]. Moreover, FGFR2-deficient mice with conditional deletion of FGFR2 exhibit decreased bone formation and reduced proliferation of OB progenitor cells [64].

PTH is a positive regulator of osteoblastogenesis [65]. PTH induces the proliferation of OB progenitor cells, OB lineage commitment, and maturation in osteoblastogenesis [66]. PTH binding to the PTH receptor induces cAMP/PKA downstream signaling to phosphorylate and activate CREB, a member of a large family of basic leucine zipper domain DNA-binding proteins (Figure 2) [65,67,68]. Activated CREB induces the expression of osteoblastogenic markers, such as OCN and BSP, leading to bone formation [68,69]. Moreover, PTH-activated CREB effectively induces BMP-2 expression [68]. Mice with a conditional deletion of the G-protein coupled type 1 PTH receptor in OBs exhibit disrupted trabecular bone formation resulting from reduced OB activity [70].

Hh signaling is involved in promoting osteoblastogenesis [71,72]. Hh signaling activates glioma-associated oncogene (Gli) transcription factors by releasing the membrane protein smoothened, which triggers signaling cascade, and the activated Gli transcription factor travels to the nucleus to stimulate RUNX2/OSX activation in osteoblastogenesis (Figure 2) [73]. In rat MSCs, Hh also induces OB proliferation and differentiation by RUNX2-induced ALP, OCN, and COL1A1 expression [74]. Moreover, Hh and BMP synergistically induce osteoblastogenesis in the endochondral skeleton [75].

5. Cytokine Regulation of Osteoblastogenesis

Osteoblastogenesis is tightly regulated by complex cytokine networks under physiological and pathophysiological conditions [76]. Osteoblastogenic cytokines, such as interleukin-10 (IL-10), IL-11, IL-18, interferon-γ (IFN-γ), cardiotrophin-1 (CT-1), and oncostatin M (OSM), promote osteoblastogenesis, whereas anti-osteoblastogenic cytokines, such as tumor necrosis factor-α (TNF-α), TNF-β, IL-1α, IL-4, IL-7, IL-12, IL-13, IL-23, IFN-
α, IFN-β, leukemia inhibitory factor (LIF), cardiotrophin-like cytokine (CLC) and ciliary neurotrophic factor (CNTF), downregulate osteoblastogenesis (Table 1).

**Table 1.** Summary of the effects of osteoblastogenic and anti-osteoblastogenic factors in osteoblastogenesis.

| Factor       | Action                                                                 | Ref.       |
|--------------|------------------------------------------------------------------------|------------|
| **Osteoblastogenic factor** |                                                                      |            |
| Wnt          | induces RUNX2-mediated OB differentiation by canonical/non-canonical Wnt signaling | [41–47]    |
| BMP          | induces RUNX2/OSX-mediated OB differentiation by Smad dependent/independent signaling | [48–53]    |
| TGF-β        | induces RUNX2-mediated OB differentiation and inhibits OB apoptosis by Smad dependent/independent signaling | [54–59]    |
| FGF          | induces RUNX2-mediated OB differentiation/proliferation by PI3K/PLCγ/ERK signaling | [60–64]    |
| PTH          | induces CREB-mediated OB differentiation/proliferation by cAMP/PKA signaling | [65–70]    |
| Hh           | induces Gli/RUNX2/OSX-mediated OB differentiation/proliferation        | [71–75]    |
| IL-10        | indirectly induces bone formation by p38 MAPK signaling                 | [77,78]    |
| IL-11        | induces OB differentiation by suppressing Wnt signaling inhibitor       | [79–81]    |
| IL-18        | induces OB proliferation                                               | [82]       |
| IFN-γ        | induces RUNX2/OSX-mediated OB differentiation                          | [83–87]    |
| OSM          | induces OB differentiation by suppressing bone formation inhibitor      | [88]       |
| CT-1         | induces RUNX2-mediated OB differentiation                              | [89,90]    |
| **Anti-osteoblastogenic factors** |                                                                      |            |
| TNF-α        | inhibits RUNX2-AP-1 or SATB2-mediated OB differentiation/proliferation | [91–98]    |
| TNF-β        | inhibits RUNX2-mediated OB differentiation                             | [99]       |
| IL-1α        | inhibits OB differentiation and induces OB apoptosis by JNK/p38 MAPK signaling | [100]      |
| IL-4/13      | inhibits PTH-induced OB differentiation/proliferation by downregulating PTH-mediated signaling | [101–104] |
| IL-7         | inhibits RUNX2/OSX-mediated OB differentiation by downregulating MAPK signaling | [105–107] |
| IL-12/23     | inhibits OB differentiation by stimulating CD4+ T cells                | [108,109]  |
| LIF          | inhibits RUNX2-mediated OB differentiation by STAT3 signaling          | [110–112]  |
| CLC          | inhibits OB differentiation by STAT1/3 signaling pathway               | [113]      |
| CNTF         | inhibits RUNX2/OSX-mediated OB differentiation                         | [114,115]  |
| IFN-α        | inhibits BMP-induced OB differentiation/proliferation                 | [116]      |
| IFN-β        | inhibits bone formation and matrix mineralization                      | [117,118]  |
| **Ambiguous roles** |                                                                      |            |
| IL-1β        | induces OB differentiation by non-canonical Wnt signaling              | [119–121]  |
|              | inhibits RUNX2/OSX-mediated OB differentiation in inflammatory condition |            |
| IL-3         | induces RUNX2/OSX- or BMP-mediated OB differentiation                   | [122,123]  |
|              | inhibits BMP-induced OB differentiation in multiple myeloma            |            |
| IL-6         | induces RUNX2-mediated OB differentiation and matrix mineralization by STAT3-dependent ROR2 induction | [124–128]  |
|              | inhibits RUNX2/OSX-mediated OB differentiation by downregulating BMP-mediated signaling |            |
| IL-15        | induces matrix mineralization                                          | [129,130]  |
|              | induces OB apoptosis via NK cell activation                             |            |
Table 1. Cont.

| Factor | Action | Ref. |
|--------|--------|------|
| IL-17  | induces OB differentiation; exhibits synergistic effects with BMP signaling inhibits RUNX2/OSX-mediated or Wnt/BMP-induced OB differentiation | [131–140] |
| IL-37  | induces RUNX2-mediated OB differentiation by PI3K/AKT signaling inhibits BMP-induced OB differentiation in chronic inflammatory conditions | [141,142] |

Ref., references.

TNF-α is a proinflammatory cytokine that plays an important role in bone diseases [3]. TNF-α inhibits RUNX2 expression and RUNX2-induced osteoblastogenic marker expression in OB precursors and MC3T3-E1 preosteoblastic cells [91,92]. TNF-α blocks osteoblastogenic marker expression by osteoblastogenic mediator β-glycerophosphate-induced RUNX2 activation via the TNF type 1 receptor [93]. TNF-α is also reported to inhibit BMP-induced osteoblastogenesis by activating JNK signaling and suppressing BMP/Smad signaling [94]. In addition, the expression of nephroectin, an extracellular matrix protein considered to be a positive regulator of osteoblastogenesis, is suppressed by TNF-α in MC3T3-E1 preosteoblastic cells [95]. TNF-α abrogates OB lineage commitment in osteoblastogenesis by increasing ubiquitin E3 ligase Wwp1 expression, leading to proteasomal degradation of the AP-1 transcription factor [96]. TNF-α also inhibits the expression of osteoblastogenic transcription factor SATB2 via the BMP/Smad, NF-κB and MAPK signaling pathways in osteoblastogenesis [97]. In estrogen deficiency-induced osteoporosis, TNF-α inhibits OB proliferation and differentiation by upregulating P2YR expression via the ERK/JNK signaling pathways [98]. In addition to TNF-α, a recent study reported that TNF-β inhibits the early stage of osteoblastogenic differentiation from MSCs by downregulating RUNX2 and activating NF-κB [99]. Taken together, TNF-α and TNF-β are known to be strong anti-osteoblastogenic cytokines.

IL-1 is a potent proinflammatory cytokine that exists in two forms: IL-1α and IL-1β [100]. IL-1α induces OB apoptosis and inhibits osteoblastogenesis by activating the JNK/p38 MAPK pathway, while IL-1β induces OB differentiation from MSCs and matrix mineralization through activation of the non-canonical Wnt (Wnt5a/ROR2) signaling pathway [100,119]. However, inhibitory functions of IL-1β in OB differentiation and bone formation were also reported [120]. Under inflammatory conditions, IL-1β and TNF-α are reported to suppress OB differentiation from MSCs and matrix mineralization by downregulating osteoblastogenic markers, such as RUNX2, OSX, ALP, and COL1A1 [121]. IL-18, a proinflammatory cytokine belonging to the IL-1 family, acts as a mitogen in OB proliferation [82]. IL-37, an anti-inflammatory cytokine belonging to the IL-1 family, promotes osteoblastogenesis by inducing osteoblastogenic markers, such as RUNX2, ALP, OCN, and COL1A1, by activating the PI3K/AKT pathway [141]. In contrast, the anti-osteoblastogenic role of IL-37, which suppresses BMP-2 and ALP expression, has been documented in chronic inflammatory conditions, such as calcific aortic valve disease [142]. Thus, IL-1 family cytokines play important roles in osteoblastogenesis, depending on physiological and pathophysiologica status.

IL-3 is a multicolony stimulating factor produced by T cells [2,143]. In osteoblastogenesis, IL-3 induces OB differentiation and matrix mineralization by activating RUNX2 and OSX, leading to the expression of osteoblastogenic markers, such as ALP, OPN, OCN, and COL1A1 [122]. IL-3 indirectly induces osteoblastogenesis by inducing BMP-2 expression through the Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT) signaling pathway [122]. In contrast, it has been reported that BMP-2-mediated osteoblastogenesis is inhibited in multiple myeloma patients with high IL-3 levels [123]. Thus, IL-3 plays an important role in osteoblastogenesis depending on physiological and pathophysiologica status.
IL-4 is an anti-inflammatory cytokine that shares some biological similarities with IL-13 [101]. IL-4 and IL-13 inhibit osteoblastogenesis by downregulating PTH-induced ALP activity in MC3T3-E1 preosteoblastic cells [101]. IL-4 and IL-13 also inhibit the proliferation of human OBs and induce IL-6 production in these cells to regulate OC recruitment [102,103]. IL-4 inhibits ALP expression and matrix mineralization in MC3T3 preosteoblastic cells [104]. Taken together, these findings indicate that IL-4 and IL-13 are anti-osteoblastogenic cytokines.

The IL-6 family of cytokines consists of IL-6, IL-11, OSM, CT-1, LIF, CLC, and CNTF [144]. In murine calvarial OBs and MC3T3-E1 preosteoblastic cells, IL-6 inhibits osteoblastogenesis and matrix mineralization by downregulating osteoblastogenic markers, such as RUNX2, OSX, and OCN [124]. Moreover, IL-6 depletion increases BMP2/7-induced osteoblastogenesis in KS483 preosteoblastic cells [125]. In contrast, in periodontal ligament cells, IL-6 exerts osteoblastogenic effects by enhancing RUNX2 and ALP expression [126]. IL-6 also increases ALP activity and matrix mineralization in human adipose stem cells [127]. IL-6 also increases ALP activity and matrix mineralization in human adipose tissue-derived MSCs [128]. Thus, the functional role of IL-6 in osteoblastogenesis is still controversial.

The IL-6 family member IL-11 is produced in response to IL-1, TNF-α, TGF-β, PTH, and mechanical stress in OB lineage cells [145–147]. IL-11 induces osteoblastogenesis by suppressing Dickkopf1/2 inhibitors of Wnt signaling [79]. Moreover, IL-11 induces osteoblastogenesis synergistically with BMP-2 by increasing osteoblastogenic markers, such as ALP, OCN, BSP and PTH receptor [80,81]. Similarly, OSM directly stimulates OB commitment from MSCs, OB differentiation, and matrix mineralization by suppressing sclerostin, a potent inhibitor of bone formation secreted by OSs [88]. CT-1 is capable of increasing OB activity through the activation of RUNX2, CAAT/enhancer-binding protein-δ (C/EBP-δ) and C/EBP-β [89,90]. Moreover, CT-1-deficient mice showed reduced OB numbers [89]. However, the IL-6 family member LIF inhibits osteoblastogenesis at the early stages through the STAT3 signaling pathway [110,111]. LIF receptor overexpression in human MSCs suppresses osteoblastogenesis by downregulating RUNX2, ALP, and ONN, while LIF receptor depletion by siRNA knockdown enhances osteoblastogenesis [112]. The IL-6 family member CLC1 is reported to prevent OB differentiation from MSCs and matrix mineralization through STAT1/3 signaling pathways [113]. CNTF, another member of the IL-6 family of cytokines, inhibits matrix mineralization and OSX expression in OBs [114]. CNTF-deficient mice exhibited increased OB numbers and high mineralization rates [114]. Moreover, myogenic CNTF suppresses the expression of osteoblastogenic markers, such as RUNX2, OSX, ALP, OCN, and PTH receptors, in murine calvarial OBs [115]. Taken together, in the IL-6 family members, IL-11, OSM, and CT-1 exert osteoblastogenic effects, while LIF, CLC, and CNTF are anti-osteoblastogenic cytokines.

IL-7 is a crucial cytokine in B and T cell lymphopoiesis [148]. It has been reported that direct injection of IL-7 in mice inhibits bone formation [105]. In periodontal ligament stem cells, IL-7 suppresses osteoblastogenesis by downregulating osteoblastogenic markers, such as RUNX2, OSX, ALP, and OCN, through the inactivation of the MAPK pathway [106]. In multiple myeloma, IL-7 is implicated in inhibiting bone formation by suppressing RUNX2 activity [107]. Moreover, in estrogen deficiency, IL-7 inhibits osteoblastogenesis by reducing RUNX2 activation [105]. Thus, IL-7 is a potent inhibitor of osteoblastogenesis in both physiological and pathophysiological states.

IL-10 is an anti-inflammatory cytokine [2]. The osteoblastogenic properties of IL-10 are less thoroughly documented than those of other cytokines. Low physiological concentrations of IL-10 induce osteoblastogenesis by activating the p38 MAPK signaling pathway in human MSCs, while higher pathological doses of IL-10 inhibit osteoblastogenesis by activating NF-κB signaling [77]. Moreover, IL-10-deficient mice exhibit reduced bone formation [78]. Thus, IL-10 can be considered a potential osteoblastogenic cytokine.

IL-12 and IL-23 are proinflammatory cytokines belonging to the IL-12 family [2,76,148]. IL-12/IL-23-deficient mice, defective in both IL-12 and IL-23, have been reported to have
enhanced bone formation in the distal femur [108]. Moreover, IL-12 and IL-23 indirectly inhibit osteoblastogenesis by stimulating CD4+ T cells [108]. Enhanced bone formation in IL-12p40-deficient mice was protective against age-related bone loss [109]. Collectively, IL-12 and IL-23 are potential anti-osteoblastogenic cytokines.

IL-15 is a proinflammatory cytokine that shares most of its biological activities with IL-2 [149]. Elevated levels of IL-15 have been reported in inflammatory bone diseases, such as RA and periodontal disease [129]. IL-15 stimulates apoptosis of OBs via activation of NK cells [129]. However, IL-15Rα deficiency decreases OB function and bone mineralization [130]. Thus, the role of IL-15 in osteoblastogenesis remains controversial.

IL-17 is a proinflammatory cytokine predominantly produced by T helper 17 (Th17) cells, dendritic cells, and other immune cells [150]. It has been reported that OB maturation is stimulated by proinflammatory Th17 cells [131]. IL-17 produced by Th17 cells induces OB maturation of human MSCs [132]. Furthermore, IL-17 exhibits synergistic effects with BMP-2 in matrix mineralization and bone formation [132,133]. In a recent study, IL-17 was implicated in accelerating OB differentiation, matrix mineralization, and proliferation in mouse calvarial OBs [134]. Osteogenic differentiation of MSCs induced by IL-17 is further enhanced by coculture with OSs, indicating that IL-17 alters the MSC niche to induce osteoblastogenesis in cooperation with OSs [135]. In ankylosing spondylitis, IL-17 induces osteoblastogenesis by activating the JAK2/STAT3 pathway [136,137]. In contrast, IL-17 has been reported to inhibit osteoblastogenesis in rat calvarial OB precursors, with reduced expression of OSX, ALP, and OCN [138]. Similarly, an inhibitory effect of IL-17 on calvarial OB differentiation via regulation of canonical Wnt signaling pathway components has been reported in a spondyloarthritis model [139]. Furthermore, IL-17 inhibited BMP-2-induced osteoblastogenesis by downregulating osteoblastogenic markers, such as RUNX2, ALP, and OCN [140]. Thus, the role of IL-17 in osteoblastogenesis is still controversial.

IFN-γ is a well-known inhibitor of OC differentiation, but its role in osteoblastogenesis is also documented [2,151]. IFN-γ promotes osteoblastogenesis by inducing the expression of osteoblastogenic markers, such as RUNX2, OSX, ALP, and OCN [83–85]. IFN-γ deficiency or knockdown in human MSCs inhibits osteoblastogenesis by downregulating RUNX2 expression [86,87]. Moreover, IFN-γ receptor-deficient mice exhibit decreased OB differentiation capacity [87]. However, it has also been reported that IFN-γ and TNF-α synergistically promote OB apoptosis by inducing nitric oxide production or mitochondrial cytochrome c release, downregulating B cell lymphoma 2 expression and activating caspases [152,153]. IFN-α inhibits OB progenitor proliferation and differentiation by inhibiting ALP activity and downregulating BMP-2 expression [116]. Moreover, IFN-β exerts inhibitory effects on matrix mineralization by reducing the expression of COL1A1, fibronectin, fibrillin, and laminin [117]. Moreover, it has been recently reported that DEF6, also known as IFN regulatory factor 4-binding protein, suppresses osteoblastogenesis via endogenous type 1 IFN-mediated feedback inhibition [118]. Taken together, these findings indicate that IFN-γ is an osteoblastogenic cytokine, although some exceptions may exist, while IFN-α/β is a potential anti-osteoblastogenic cytokine.

6. Concluding Remarks

Over the decades, the field of osteoimmunology has advanced to demonstrate the vital role played by cytokines in osteoblastogenesis and osteoclastogenesis and elucidate the potential use of such cytokines in clinical therapeutics. In particular, osteoblastogenic and anti-osteoblastogenic cytokines play an important role in osteoblastogenesis by linking the skeletal and immune systems. Dysregulation of osteoblastogenic and anti-osteoblastogenic cytokines can have a deleterious effect on bone metabolism homeostasis. TNF-α, TNF-β, IL-1α, IL-4, IL-7, IL-12, IL-13, IL-23, IFN-α, IFN-β, LIF, CLC, and CNTF act as potent inhibitors of osteoblastogenesis, whereas IL-10, IL-11, IL-18, IFN-γ, CT-1, and OSM are osteoblastogenic (Table 1). Though each cytokine is supposed to have either stimulatory or inhibitory properties in osteoblastogenesis, the physiological mechanisms of action are...
complicated and possibly dependent on developmental stage, pathophysiological status, cytokine level, and the nature of the target cells.

**Author Contributions:** D.S.A. wrote the manuscript; S.K. contributed to the preparation of table and figure design; J.R. supervised the research and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was supported by the research fund of Chungnam National University.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no potential conflict of interest.

**References**

1. Berendsen, A.D.; Olsen, B.R. Bone development. *Bone* 2015, 80, 14–18. [CrossRef]
2. Amarasekara, D.S.; Yun, H.; Kim, S.; Lee, N.; Kim, H.; Rho, J. Regulation of Osteoclast Differentiation by Cytokine Networks. *Immune Netw.* 2018, 18, e8. [CrossRef] [PubMed]
3. Amarasekara, D.S.; Yu, J.; Rho, J. Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases. *J. Immunol. Res.* 2015, 2015, 832127. [CrossRef] [PubMed]
4. Huang, W.; Yang, S.; Shao, J.; Li, Y.-P. Signaling and transcriptional regulation in osteoblast commitment and differentiation. *Front. Biosci.* A J. Virtual Libr. 2007, 12, 3068–3092. [CrossRef] [PubMed]
5. Qiu, Z.-Y.; Cui, H.; Wang, X.-M. Natural bone tissue and its biomimetic. In *Mineralized Collagen Bone Graft Substitutes*; Wang, X.-M., Qiu, Z.-Y., Cui, H., Eds.; Woodhead Publishing: Sawston, UK, 2019; Chapter 1; pp. 1–22.
6. Feldman, D.; Pike, J.W.; Glorieux, F.H. *Vitamin D*, 2nd ed.; Academic Press: Burlington, VT, USA, 2005; pp. 1845–1892.
7. Stein, G.S.; Lian, J.B. Molecular Mechanisms Mediating Proliferation/Differentiation Interrelationships during Progressive Development of the Osteoblast Phenotype. *Endocr. Rev.* 1993, 14, 424–442. [CrossRef]
8. Rutkovskiy, A.; Stensløkken, K.-O.; Vaage, I.J. Osteoblast Differentiation at a Glance. *Med. Sci. Monit.* Basic Res. 2016, 22, 95–106. [CrossRef]
9. Glass, D.A.; Bialek, P.; Ahn, J.D.; Starbuck, M.; Patel, M.S.; Clevers, H.; Taketo, M.M.; Long, F.; McMahon, A.P.; Lang, R.A.; et al. Canonical Wnt Signaling in Differentiated Osteoblasts Controls Osteoclast Differentiation. *Dev. Cell* 2005, 8, 751–764. [CrossRef]
10. Lin, X.; Patil, S.; Gao, Y.-G.; Qian, A. The Bone Extracellular Matrix in Bone Formation and Regeneration. *Front. Pharmacol.* 2020, 11, 757. [CrossRef] [PubMed]
11. Cremers, S.; Garnero, P.; Seibel, M.J. Biochemical Markers of Bone Metabolism. In *Principles of Bone Biology*, 3rd ed.; Bilezikian, J.P., Raisz, L.G., Martin, T.J., Eds.; Academic Press: San Diego, CA, USA, 2008; Chapter 87, pp. 1857–1881.
12. Boyce, B.F.; Xing, L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. *Arch. Biochem. Biophys.* 2008, 473, 139–146. [CrossRef]
13. Horowitz, M.C.; Lorenzo, J.A. Local Regulators of Bone: IL-1, TNF, Lymphotoxin, Interferon-γ, the LIF/IL-6 Family, and Additional Cytokines. In *Principles of Bone Biology*, 3rd ed.; Bilezikian, J.P., Raisz, L.G., Martin, T.J., Eds.; Academic Press: San Diego, CA, USA, 2008; Chapter 57, pp. 1209–1234.
14. Karsenty, G. Transcriptional control of osteoblast differentiation and function. In *Principles of Bone Biology*, 4th ed.; Bilezikian, J.P., Martin, T.J., Clemens, T.L., Rosen, C.J., Eds.; Academic Press: San Diego, CA, USA, 2020; Chapter 7, pp. 163–176.
15. Komori, T. Regulation of bone development and extracellular matrix protein genes by RUNX2. *Cell Tissue Res.* 2009, 339, 189. [CrossRef]
16. Schroeder, T.M.; Jensen, E.D.; Westendorf, J.J. Runx2: A master organizer of gene transcription in developing and maturing osteoblasts. *Birth Defects Res. C Embryo Today* 2005, 75, 213–225. [CrossRef] [PubMed]
17. Lee, K.S.; Kim, H.J.; Chi, X.Z.; Ueta, C.; Komori, T.; Wozney, J.M.; Kim, E.G.; Choi, J.Y.; Ryoo, H.M.; et al. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. *Mol. Cell Biol.* 2000, 20, 8783–8792. [CrossRef]
18. Komori, T.; Yagi, H.; Nomura, S.; Yamaguchi, A.; Sasaki, K.; Deguchi, K.; Shimizu, Y.; Bronson, R.T.; Gao, Y.H.; Inada, M.; et al. Targeted Disruption of Cbfa1 Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts. *Cell* 1997, 89, 755–764. [CrossRef]
19. Narayanian, A.; Srinatha, N.; Rohini, M.; Selvamurugan, N. Regulation of Runx2 by MicroRNAs in osteoblast differentiation. *Life Sci.* 2019, 232, 116676. [CrossRef] [PubMed]
20. Maruyama, Z.; Yoshida, C.A.; Furuichi, T.; Amizuka, N.; Ito, M.; Fukuyama, R.; Miyazaki, T.; Kitaura, H.; Nakamura, K.; Fujita, T.; et al. Runx2 determines bone maturity and turnover rate in postnatal bone development and is involved in bone loss in estrogen deficiency. *Dev. Dyn.* 2007, 236, 1876–1890. [CrossRef]
21. Qin, X.; Jiang, Q.; Miyazaki, T.; Komori, T. Runx2 regulates cranial suture closure by inducing hedgehog, Fgf, Wnt and Pthlh signaling pathway gene expressions in suture mesenchymal cells. *Hum. Mol. Genet.* 2019, 28, 896–911. [CrossRef]

22. Nakashima, K.; Zhou, X.; Kunigel, G.; Zhang, Z.; Deng, J.M.; Behringer, R.R.; de Crombrugghe, B. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. *Cell* 2002, 108, 17–29. [CrossRef]

23. Liu, Q.; Li, M.; Wang, S.; Xiao, Z.; Xiong, Y.; Wang, G. Recent Advances of Osterix Transcription Factor in Osteoblast Differentiation and Bone Formation. *Front. Cell Dev. Biol.* 2020, 8. [CrossRef]

24. Renn, J.; Winkler, C. Osterix-mCherry transgenic medaka for in vivo imaging of bone formation. *Dev. Dyn.* 2009, 238, 241–248. [CrossRef]

25. Kawane, T.; Qin, X.; Jiang, Q.; Miyazaki, T.; Komori, H.; Yoshida, C.A.; Matsuura-Kawata, V.; Sakane, C.; Matsuo, Y.; Nagai, K.; et al. Runx2 is required for the proliferation of osteoblast progenitors and induces proliferation by regulating Fgfr2 and Fgfr3. *Sci. Rep.* 2018, 8, 13551. [CrossRef]

26. Yang, S.; Hu, L.; Wang, C.; Wei, F. PERK-eIF2α-ATF4 signaling contributes to osteogenic differentiation of periodontal ligament stem cells. *J. Mol. Histol.* 2020, 51, 125–135. [CrossRef]

27. Yang, X.; Karsenty, G. ATF4, the osteoblast accumulation of which is determined post-translationally, can induce osteoblast-specific gene expression in non-osteoblastic cells. *J. Biol. Chem.* 2004, 279, 47109–47114. [CrossRef]

28. Xiao, G.; Jiang, D.; Ge, C.; Zhao, Z.; Lai, Y.; Boules, H.; Phimphilai, M.; Yang, X.; Karsenty, G.; Franceschi, R.T. Cooperative interactions between activating transcription factor 4 and Runx2/Cbfa1 stimulate osteoblast-specific osteocalcin gene expression. *J. Biol. Chem.* 2005, 280, 30689–30696. [CrossRef] [PubMed]

29. Yu, S.; Zhu, K.; Lai, Y.; Zhao, Z.; Fan, J.; Im, H.-J.; Chen, D.; Xiao, G. atf4 promotes β-catenin expression and osteoblastic differentiation of bone marrow mesenchymal stem cells. *Int. J. Biol. Sci.* 2013, 9, 256–266. [CrossRef] [PubMed]

30. Tang, J.; Xie, J.; Chen, W.; Tang, C.; Wu, J.; Wang, Y.; Zhou, X.-D.; Zhou, H.-D.; Li, Y.-P. Runx1 transcription factor 1 is required for murine osteoblast differentiation and bone formation. *J. Biol. Chem.* 2020, 295, 11669–11681. [CrossRef]

31. Kawamata, A.; Bakiri, L.; Jimenez, M.; Schinke, T.; Amling, M.; Wagner, E.F. Fra-2/AP-1 controls bone formation by regulating Hedgehogs, and Cbfa1. *Endocr. Rev.* 2008, 29, 393–411. [CrossRef] [PubMed]

32. Tang, C.-Y.; Wu, M.; Zhao, D.; Edwards, D.; McVicar, A.; Luo, Y.; Zhu, G.; Wang, Y.; Zhou, H.-D.; Chen, W.; et al. Runx1 up-regulates chondrocyte to osteoblast lineage commitment and promotes bone formation by enhancing both chondrogenesis and osteogenesis. *Biochem. J.* 2020, 477, 2421–2438. [CrossRef]

33. Komiya, Y.; Habas, R. Wnt signal transduction pathways. *Organogenesis* 2008, 4, 68–75. [CrossRef] [PubMed]

34. Houshyar, K.S.; Tapking, C.; Borrelli, M.R.; Popp, D.; Duscher, D.; Maan, Z.N.; Chelliah, M.P.; Li, J.; Harati, K.; Wallner, C.; et al. Wnt Pathway in Bone Repair and Regeneration—What Do We Know So Far. *Front. Cell Dev. Biol.* 2019, 6. [CrossRef] [PubMed]

35. Kawane, T.; Qin, X.; Jiang, Q.; Miyazaki, T.; Komori, H.; Yoshida, C.A.; Matsuura-Kawata, V.; Sakane, C.; Matsuo, Y.; Nagai, K.; et al. Runx2 is required for the proliferation of osteoblast progenitors and induces proliferation by regulating Fgfr2 and Fgfr3. *Sci. Rep.* 2018, 8, 13551. [CrossRef]

36. Yang, S.; Hu, L.; Wang, C.; Wei, F. PERK-eIF2α-ATF4 signaling contributes to osteogenic differentiation of periodontal ligament stem cells. *J. Mol. Histol.* 2020, 51, 125–135. [CrossRef]

37. Yang, X.; Karsenty, G. ATF4, the osteoblast accumulation of which is determined post-translationally, can induce osteoblast-specific gene expression in non-osteoblastic cells. *J. Biol. Chem.* 2004, 279, 47109–47114. [CrossRef]

38. Dobreva, G.; Chahrour, M.; Dautzenberg, M.; Chirivella, L.; Kanzler, B.; Fariñas, I.; Karsenty, G.; Grosschedl, R. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. *J. Biol. Chem.* 2005, 280, 30689–30696. [CrossRef] [PubMed]

39. Bozec, A.; Bakiri, L.; Jimenez, M.; Schinke, T.; Amling, M.; Wagner, E.F. Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production. *J. Cell. Physiol.* 2010, 190, 1093–1106. [CrossRef]

40. Zhang, J.; Tu, Q.; Grosschedl, R.; Kim, M.S.; Griffin, T.; Drissi, H.; Yang, P.; Chen, J. Roles of SATB2 in osteogenic differentiation and bone regeneration. *Tissue Eng. Part A* 2011, 17, 1767–1776. [CrossRef] [PubMed]

41. Dowrey, T.; Schwartz, E.E.; Duong, J.; Merkuri, F.; Zarate, Y.A.; Fish, J.L. Satb2 regulates proliferation and nuclear integrity of osteoblast progenitors and induces proliferation by regulating Fgfr2 and Fgfr3. *Sci. Rep.* 2020, 8, 13551. [CrossRef]

42. Karsenty, G.; Wagner, E.F. Reaching a genetic and molecular understanding of skeletal development. *Dev. Cell* 2002, 2, 389–406. [CrossRef]

43. Bozec, A.; Bakiri, L.; Jimenez, M.; Schinke, T.; Amling, M.; Wagner, E.F. Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production. *J. Cell. Physiol.* 2010, 190, 1093–1106. [CrossRef]

44. Zhang, J.; Tu, Q.; Grosschedl, R.; Kim, M.S.; Griffin, T.; Drissi, H.; Yang, P.; Chen, J. Roles of SATB2 in osteogenic differentiation and bone regeneration. *Tissue Eng. Part A* 2011, 17, 1767–1776. [CrossRef] [PubMed]

45. Dowrey, T.; Schwartz, E.E.; Duong, J.; Merkuri, F.; Zarate, Y.A.; Fish, J.L. Satb2 regulates proliferation and nuclear integrity of pre-osteoblasts. *Bone* 2019, 127, 488–498. [CrossRef]

46. Bozec, A.; Bakiri, L.; Jimenez, M.; Schinke, T.; Amling, M.; Wagner, E.F. Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production. *J. Cell. Physiol.* 2010, 190, 1093–1106. [CrossRef]

47. Zayzafoon, M. Calcium/calmodulin signaling controls osteoblast growth and differentiation. *J. Cell Biochem.* 2006, 97, 56–70. [CrossRef] [PubMed]

48. Yamaguchi, A.; Komori, T.; Suda, T. Regulation of Osteoblast Differentiation Mediated by Bone Morphogenetic Proteins, Hedgehogs, and Cbfa1. *Endocr. Rev.* 2000, 21, 393–411. [CrossRef] [PubMed]
75. Long, F.; Chung, U.I.; Ohba, S.; McMahon, J.; Kronenberg, H.M.; McMahon, A.P. Ihh signaling is directly required for the osteoblast lineage in the endochondral skeleton. Development 2004, 131, 1309–1318. [CrossRef]

76. Zheng, M.H.; Wood, D.J.; Papadimitriou, J.M. What’s new in the role of cytokines on osteoblast proliferation and differentiation? Pathol. Res. Pract. 1992, 188, 1104–1121. [CrossRef]

77. Chen, E.; Liu, G.; Zhou, Z.; Zhang, W.; Wang, C.; Hu, D.; Xue, D.; Pan, Z. Concentration-dependent, dual roles of IL-10 in the osteogenesis of human BMSCs via P38/ MAPK and NF-kappaB signaling pathways. FASEB J. 2018, 32, 4917–4929. [CrossRef]

78. Dresner-Pollak, R.; Gelb, N.; Rachmilewitz, D.; Karmeli, F.; Weinreb, M. Interleukin 10-deficient mice develop osteopenia, decreased bone formation, and mechanical fragility of long bones. Gastroenterology 2004, 127, 792–801. [CrossRef]

79. Matsumoto, T.; Kuriwaka-Kido, R.; Kondo, T.; Endo, I.; Kido, S. Regulation of osteoblast differentiation by interleukin-11 via AP-1 and Smad signaling. Endocr. J. 2012, 59, 91–101. [CrossRef] [PubMed]

80. Suga, K.; Saitoh, M.; Fukushima, S.; Takahashi, K.; Nara, H.; Yasuda, S.; Miyata, K. Interleukin-11 induces osteoblast differentiation and acts synergistically with bone morphogenetic protein-2 in C3H10T1/2 cells. J. Interferon Cytokine Res. 2001, 21, 695–707. [CrossRef] [PubMed]

81. Suga, K.; Saitoh, M.; Kubo, S.; Fukushima, S.; Kaku, S.; Yasuda, S.; Miyata, K. Interleukin-11 acts synergistically with bone morphogenetic protein-2 to accelerate bone formation in a rat ectopic model. J. Interferon Cytokine Res. 2003, 23, 203–207. [CrossRef] [PubMed]

82. Cornish, J.; Gillespie, M.T.; Callon, K.E.; Horwood, N.J.; Moseley, J.M.; Reid, I.R. Interleukin-18 Is a Novel Mitogen of Osteogenic Mesenchymal Stem Cells. Endocr. J. 2003, 44, 1194–1201. [CrossRef] [PubMed]

83. Gowen, M.; MacDonald, B.R.; Russell, R.G. Actions of recombinant human gamma interferon and tumor necrosis factor alpha on the proliferation and osteoblastic characteristics of human trabecular bone cells in vitro. Arthritis Rheum. 1988, 31, 1500–1507. [CrossRef] [PubMed]

84. Maruhashi, T.; Kaitu, T.; Yabe, R.; Seno, A.; Chung, S.H.; Fujikado, N.; Iwakura, Y. DCIR maintains bone homeostasis by regulating IFN-gamma production in T cells. J. Immunol. 2015, 194, 5681–5691. [CrossRef] [PubMed]

85. Vidal, C.; Bermeo, S.; Li, W.; Huang, D.; Kremer, R.; Duque, G. Interferon gamma inhibits adipogenesis in vitro and prevents marrow fat infiltration in oophorectomized mice. Stem Cells 2012, 30, 1042–1048. [CrossRef]

86. Duque, G.; Huang, D.C.; Dion, N.; Macoritto, M.; Rivas, D.; Li, W.; Yang, X.F.; Li, J.; Lian, J.; Marino, F.T.; et al. Interferon-gamma plays a role in bone formation and rescues osteoporosis in ovarioectomized mice. J. Bone Miner. Res. 2011, 26, 1472–1483. [CrossRef]

87. Duque, G.; Huang, D.C.; Macoritto, M.; Rivas, D.; Yang, X.F.; Ste-Marie, L.G.; Kremer, R. Autocrine regulation of interferon gamma in mesenchymal stem cells plays a role in early osteoblastogenesis. Stem Cells 2009, 27, 550–558. [CrossRef] [PubMed]

88. Sims, N.A.; Quinn, J.M.W. Osteoimmunology: Oncostatin M as a pleiotropic regulator of bone formation and resorption in health and disease. Bonekey Rep. 2014, 3, 527. [CrossRef] [PubMed]

89. Walker, E.C.; McGregor, N.E.; Poulton, I.J.; Pompolo, S.; Allan, E.H.; Quinn, J.M.; Gillespie, M.T.; Martin, T.J.; Sims, N.A. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J. Bone Miner. Res. 2008, 23, 2025–2032. [CrossRef]

90. Quach, J.M.; Walker, E.C.; Allan, E.; Solano, M.; Yokoyama, A.; Kato, S.; Sims, N.A.; Gillespie, M.T.; Martin, T.J. Zinc finger protein 467 is a novel regulator of osteoblast and adipocyte commitment. J. Biol. Chem. 2011, 286, 4186–4198. [CrossRef]

91. Gilbert, L.; He, X.; Farmer, P.; Boden, S.; Kozlowski, M.; Rubin, J.; Nanes, M.S. Inhibition of Osteoblast Differentiation by Tumor Necrosis Factor-α. Endocrinology 2000, 141, 3956–3964. [CrossRef]

92. Gilbert, L.; He, X.; Farmer, P.; Rubin, J.; Drissi, H.; van Wijnen, A.J.; Lian, J.B.; Stein, G.S.; Nanes, M.S. Expression of the Osteoblast Differentiation Factor RUNX2 (Cbfal/AML3/Pebp2αA) Is Inhibited by Tumor Necrosis Factor-α. J. Biol. Chem. 2002, 277, 2695–2701. [CrossRef]

93. Abbas, S.; Zhang, Y.H.; Clohisy, J.C.; Abu-Amer, Y. Tumor necrosis factor-alpha inhibits pre-osteoblast differentiation through its type-1 receptor. Cytokine 2003, 22, 33–41. [CrossRef]

94. Mukai, T.; Otsuka, F.; Otani, H.; Yamashita, M.; Takasugi, K.; Inagaki, K.; Yamamura, M.; Makino, H. TNF-α inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. Biochem. Biophys. Res. Commun. 2007, 356, 1004–1010. [CrossRef] [PubMed]

95. Tsukasaki, M.; Yamada, A.; Suzuki, D.; Aizawa, R.; Miyamoto, Y.; Suzuki, T.; Takami, M.; Yoshimura, K.; Morimura, N.; et al. Expression of POEM, a positive regulator of osteoblast differentiation, is suppressed by TNF-α. Biochem. Biophys. Res. Commun. 2011, 410, 766–770. [CrossRef] [PubMed]

96. Zhao, L.; Huang, J.; Zhang, H.; Wang, Y.; Matesic, L.E.; Takahata, M.; Awad, H.; Chen, D.; Xing, L. Tumor necrosis factor inhibits mesenchymal stem cell differentiation into osteoblasts via the ubiquitin E3 ligase Wwp1. Stem Cells 2011, 29, 1601–1610. [CrossRef]

97. Zuo, C.; Zhao, X.; Shi, Y.; Wu, W.; Zhang, N.; Xu, J.; Wang, C.; Hu, G.; Zhang, X. TNF-α inhibits SATB2 expression and osteoblast differentiation through NF-κB and MAPK pathways. Oncotarget 2017, 9, 4833–4850. [CrossRef]

98. Du, D.; Zhou, Z.; Zhu, L.; Hu, X.; Lu, J.; Shi, C.; Chen, F.; Chen, A. TNF-α suppresses osteogenic differentiation of MSCs by accelerating P2Y2 receptor in estrogen-deficiency induced osteoporosis. Bone 2018, 117, 161–170. [CrossRef] [PubMed]

99. Constanze, B.; Popper, B.; Aggarwal, B.B.; Shakibaei, M. Evidence that TNF-β suppresses osteoblast differentiation of mesenchymal stem cells and reversatrol reverses it through modulation of NF-κB, Sirt1 and Runx2. Cell Tissue Res. 2020, 381, 83–98. [CrossRef] [PubMed]
100. Guo, C.; Yang, X.-G.; Wang, F.; Ma, X.-Y. IL-1α induces apoptosis and inhibits the osteoblast differentiation of MC3T3-E1 cells through the JNK and p38 MAPK pathways. *Int. J. Mol. Med.* **2016**, 38, 319–327. [CrossRef]

101. Ura, K.; Morimoto, I.; Watanabe, K.; Saito, K.; Yanagihara, N.; Eto, S. Interleukin (IL)-4 and IL-13 Inhibit the Differentiation of Murine Osteoblastic MC3T3-E1 Cells. *Endocr. J.* **2000**, 47, 293–302. [CrossRef] [PubMed]

102. Frost, A.; Jonsson, K.B.; Brandstrom, H.; Ljunghall, S.; Nilsson, O.; Ljunggren, O. Interleukin (IL)-13 and IL-4 inhibit proliferation and stimulate IL-6 formation in human osteoblasts: Evidence for involvement of receptor subunits IL-13R, IL-13Rα1, and IL-4Rα1. *Bone* **2001**, 28, 268–274. [CrossRef]

103. Silfverswärd, C.-J.; Frost, A.; Brändström, H.; Nilsson, O.; Ljunggren, O. Interleukin-4 and interleukin-13 potentiate interleukin-1 induced secretion of interleukin-6 in human osteoblast-like cells. *J. Orthop. Res.* **2004**, 22, 1058–1062. [CrossRef] [PubMed]

104. Riancho, J.A.; Gonzalez-Marcías, J.; Amado, J.A.; Olmos, J.M.; Fernández-Luna, J.L. Interleukin-4 as a bone regulatory factor: Effects on murine osteoblast-like cells. *J. Endocrinol. Investig.* **1995**, 18, 174–179. [CrossRef] [PubMed]

105. Weitzmann, M.N.; Roggia, C.; Toraldo, G.; Weitzmann, L.; Pacifi, R. Increased production of IL-7 un Couples bone formation from bone resorption during estrogen deficiency. *J. Clin. Invest.* **2002**, 110, 1643–1650. [CrossRef]

106. Jian, C.-X.; Fan, Q.-S.; Hu, Y.-H.; He, Y.; Li, M.-Z.; Zheng, W.-Y.; Ren, Y.; Li, C.-J. IL-7 suppresses osteogenic differentiation of periodontal ligament stem cells through inactivation of mitogen-activated protein kinase pathway. *Organogenesis* **2016**, 12, 183–193. [CrossRef]

107. Giuliani, N.; Colla, S.; Morandi, F.; Lazzaretti, M.; Sala, R.; Bonomini, S.; Grano, M.; Colucci, S.; Svaldi, M.; Rizzoli, V. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. *Blood* **2005**, 106, 2472–2483. [CrossRef] [PubMed]

108. Xu, J.; Wang, Y.; Li, J.; Zhang, X.; Geng, Y.; Huang, Y.; Dai, K.; Zhang, X. IL-12p40 impairs mesenchymal stem cell-mediated bone regeneration via CD4⁺ T cells. *Cell Death Differ.* **2016**, 23, 1941–1951. [CrossRef]

109. Xu, J.; Li, J.; Hu, Y.; Dai, K.; Gan, Y.; Zhao, J.; Huang, M.; Zhang, X. IL-23, but not IL-12, plays a critical role in inflammation-mediated bone disorders. *Theranostics* **2020**, 10, 3925–3938. [CrossRef]

110. Malaval, L.; Aubin, J.E. Biphasic effects of leukemia inhibitory factor on osteoblastic differentiation. *J. Cell Biochem.* **2001**, 81 (Suppl. S36), 63–70. [CrossRef] [PubMed]

111. Matsushita, K.; Itoh, S.; Ikeda, S.; Yamamoto, Y.; Yamauchi, Y.; Hayashi, M. LIF/STAT3/SOCS3 signaling pathway in murine bone marrow stromal cells suppresses osteoblast differentiation. *J. Cell Biochem.* **2014**, 115, 1262–1268. [CrossRef]

112. Wang, T.; Yan, R.Q.; Xu, X.Y.; Cao, L.L.; Liu, J.Y.; Zheng, M.R.; Li, W.D. Effects of Leukaemia Inhibitory Factor Receptor on the Early Stage of Osteogenic Differentiation of Human Bone Marrow Mesenchymal Cells. *Folia Biol.* **2018**, 64, 186–194.

113. Nahle, S.; Pasquin, S.; Laplante, V.; Rousseau, F.; Sharma, M.; Gauchat, J.F. Cardiotrophin-like cytokine (CLCFL1) modulates mesenchymal stem cell osteoblastic differentiation. *J. Biol. Chem.* **2019**, 294, 11952–11959. [CrossRef] [PubMed]

114. McGregor, N.E.; Poulton, I.J.; Walker, E.C.; Pompolo, S.; Quinn, J.M.W.; Martin, T.J.; Sims, N.A. Ciliary Neurotrophic Factor Inhibits Bone Formation and Plays a Sex-Specific Role in Bone Growth and Remodeling. *Calcif. Tissue Int.* **2010**, 86, 261–270. [CrossRef] [PubMed]

115. Johnson, R.W.; White, J.D.; Walker, E.C.; Martin, T.J.; Sims, N.A. Myokines (muscle-derived cytokines and chemokines) including ciliary neurotrophic factor (CNTF) inhibit osteoblast differentiation. *Bone* **2014**, 64, 47–56. [CrossRef]

116. Orefio, R.O.; Romberg, S.; Virdi, A.S.; Joyner, C.J.; Berven, S.; Triffitt, J.T. Effects of interferon alpha on human osteoprogenitor cell survival and differentiation. *Int. J. Mol. Sci.* **2018**, 19, 378–392. [CrossRef]

117. Woecckl, V.J.; Eijken, M.; van de Peppel, J.; Chiba, H.; van der Eerden, B.C.; van Leeuwen, J.P. IFNα impedes extracellular matrix formation leading to inhibition of mineralization by effects in the early stage of human osteoblast differentiation. *J. Cell Physiol.* **2012**, 227, 2668–2676. [CrossRef] [PubMed]

118. Deng, Z.; Ng, C.; Inoue, K.; Chen, Z.; Xia, Y.; Hu, X.; Greenblatt, M.; Fernis, A.; Zhao, B. Def6 regulates endogenous type-I interferon responses in osteoblasts and suppresses osteogenesis. *eLife* **2020**, 9, e59659. [CrossRef] [PubMed]

119. Sonomoto, K.; Yamaoka, K.; Oshita, K.; Fukuyo, S.; Zhang, X.; Nakano, K.; Okada, Y.; Tanaka, Y. Interleukin-1β induces differentiation of human mesenchymal stem cells into osteoblasts via the Wnt-5a/receptor tyrosine kinase-like orphan receptor 2 pathway. *Arthritis Rheum.* **2012**, 64, 3355–3363. [CrossRef] [PubMed]

120. Stashenko, P.; Dewhirst, F.E.; Rooney, M.L.; Desjardins, L.A.; Heely, J.D. Interleukin-1 beta is a potent inhibitor of bone formation in vitro. *Bone Miner. Res.* **1987**, 2, 559–565. [CrossRef] [PubMed]

121. Lacey, D.C.; Simmons, P.J.; Graves, S.E.; Hamilton, J.A. Proinflammatory cytokines inhibit osteogenic differentiation from stem cells: Implications for bone repair during inflammation. *Osteoarthr. Cartil.* **2009**, 17, 735–742. [CrossRef] [PubMed]

122. Barhanpurkar, A.P.; Gupta, N.; Srivastava, R.K.; Tomar, G.B.; Naik, S.P.; Joshi, S.R.; Pote, S.T.; Mishra, G.C.; Wani, M.R. IL-3 promotes osteoblast differentiation and bone formation in human mesenchymal stem cells. *Biochem. Biophys. Res. Commun.* **2012**, 418, 669–675. [CrossRef]

123. Ehrlich, L.A.; Chung, H.Y.; Ghobrial, I.; Choi, S.J.; Morandi, F.; Colla, S.; Rizzoli, V.; Roodman, G.D.; Giuliani, N. IL-3 is a potent inhibitor of osteoblast differentiation in multiple myeloma. *Blood* **2005**, 106, 1407–1414. [CrossRef] [PubMed]

124. Kaneshiro, S.; Ebina, K.; Shi, K.; Higuchi, C.; Hirao, M.; Okamoto, M.; Koizumi, K.; Morimoto, T.; Yoshikawa, H.; Hashimoto, J. IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro. *J. Bone Miner. Metab.* **2014**, 32, 378–392. [CrossRef]
125. Malysheva, K.; de Rooij, K.; Lowik, C.W.; Baeten, D.L.; Rose-John, S.; Stoika, R.; Korchynskyi, O. Interleukin 6/Wnt interactions in rheumatoid arthritis: Interleukin 6 inhibits Wnt signaling in synovial fibroblasts and osteoblasts. *Croat. Med. J.* **2016**, *57*, 89–98. [CrossRef]

126. Iwasaki, K.; Komaki, M.; Mimori, K.; Leon, E.; Izumi, Y.; Ishikawa, I. IL-6 induces osteoblastic differentiation of periodontal ligament cells. *J. Dent. Res.* **2008**, *87*, 937–942. [CrossRef]

127. Bastidas-Coral, A.P.; Bakker, A.D.; Zandieh-Doulabi, B.; Kleverlaan, C.J.; Bravenboer, N.; Forouzanfar, T.; Klein-Nulend, J. Cytokines TNF-α, IL-6, IL-17F, and IL-4 Differentially Affect Osteogenic Differentiation of Human Adipose Stem Cells. *Stem Cells Int.* **2016**, *2016*, 1318256. [PubMed]

128. Fukuyo, S.; Yamaoka, K.; Sonomoto, K.; Oshita, K.; Okada, Y.; Saito, K.; Yoshida, Y.; Kanazawa, T.; Minami, Y.; Tanaka, Y. IL-6-accelerated calcification by induction of ROR2 in human adipose tissue-derived mesenchymal stem cells is STAT3 dependent. *Rheumatology* **2014**, *53*, 1282–1290. [PubMed]

129. Takeshita, H.; Kikuchi, T.; Soboku, K.; Okabe, I.; Mizutani, H.; Mitani, A.; Ishihara, Y.; Noguchi, T. Effect of IL-15 and Natural Killer Cells on Osteoclasts and Osteoblasts in a Mouse Coculture. *Inflammation* **2014**, *37*, 657–669. [CrossRef] [PubMed]

130. Loro, E.; Ramaswamy, G.; Chandra, A.; Tseng, W.-J.; Mishra, M.K.; Shore, E.M.; Khurana, T.S. IL15RA is required for osteoblast function and bone mineralization. *Bone* **2017**, *103*, 20–30. [CrossRef] [PubMed]

131. Nam, D.; Mau, E.; Wang, Y.; Wright, D.; Silkstone, D.; Whetstone, H.; Alman, B. T-lymphocytes enable osteoblast maturation via IL-17F during the early phase of fracture repair. *PLoS ONE* **2012**, *7*, e40044. [CrossRef] [PubMed]

132. Croes, M.; Öner, F.C.; van Neerven, D.; Sabir, E.; Kruyt, M.C.; Dhert, W.J.A.; Alblas, J. Proinflammatory T cells and IL-17 stimulate osteoblast differentiation. *Bone* **2016**, *84*, 262–270. [CrossRef] [PubMed]

133. Croes, M.; Kruyt, M.C.; Groen, W.M.; van Dorenmalen, K.M.A.; Dhert, W.J.A.; Öner, F.C.; Alblas, J. Interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation. *Sci. Rep.* **2018**, *8*, 7269. [CrossRef] [PubMed]

134. Kim, H.J.; Seo, S.J.; Kim, J.-Y.; Kim, Y.-G.; Lee, Y. IL-17 promotes osteoblast differentiation, bone regeneration, and remodeling in mice. *Biochem. Biophys. Res. Commun.* **2020**, *524*, 1044–1050. [CrossRef] [PubMed]

135. Liao, C.; Zhang, C.; Jin, L.; Yang, Y. IL-17 alters the mesenchymal stem cell niche towards osteogenesis in cooperation with osteocytes. *J. Cell. Physiol.* **2020**, *235*, 4466–4480. [CrossRef]

136. Jo, S.; Wang, S.E.; Lee, Y.L.; Kang, S.; Lee, B.; Han, J.; Sung, I.-H.; Park, Y.-S.; Bae, S.-C.; Kim, T.-H. IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis. *Arthritis Res. Ther.* **2018**, *20*, 115. [CrossRef] [PubMed]

137. Kenna, T.J.; Davidson, S.I.; Duan, R.; Bradbury, L.A.; McFarlane, J.; Smith, M.; Weedon, H.; Street, S.; Thomas, R.; Thomas, G.P.; et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ/δ T cells in patients with active ankylosing spondylitis. *Arthritis Rheum.* **2012**, *64*, 1420–1429. [CrossRef] [PubMed]

138. Kim, Y.G.; Park, J.W.; Lee, J.M.; Suh, J.Y.; Lee, J.K.; Chang, B.S.; Um, H.S.; Kim, J.Y.; Lee, Y. IL-17 inhibits osteoblast differentiation and bone regeneration in rat. *Arch. Oral Biol.* **2014**, *59*, 897–905. [CrossRef] [PubMed]

139. Shaw, A.T.; Maeda, Y.; Gravalles, E.M. IL-17A deficiency promotes periosteal bone formation in a model of inflammatory arthritis. *Arthritis Res. Ther.* **2016**, *18*, 104. [CrossRef]

140. Zhang, J.-R.; Pang, D.-D.; Tong, Q.; Liu, X.; Su, D.-F.; Dai, S.-M. Different Modulatory Effects of IL-17, IL-22, and IL-23 on Osteoblast Differentiation. *Mediat. Inflamm.* **2017**, *2017*, 5950395. [CrossRef] [PubMed]

141. Ye, C.; Zhang, W.; Hang, K.; Chen, M.; Hou, W.; Chen, J.; Chen, X.; Chen, E.; Tang, L.; Lu, J.; et al. Extracellular IL-37 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via activation of the PI3K/AKT signaling pathway. *Cell Death Dis.* **2019**, *10*, 753. [CrossRef]

142. Zeng, Q.; Song, R.; Fullerton, D.A.; Ao, L.; Zhai, Y.; Li, S.; Ballak, D.B.; Cleveland, J.C.; Jr.; Reece, T.B.; McKinsey, T.A.; et al. Interleukin-37 suppresses the osteogenic responses of human aortic valve interstitial cells in vitro and alleviates valve lesions in mice. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 1631–1646. [CrossRef]

143. O'Shea, J.J.; Gadina, M.; Siegel, R. 9—Cytokines and cytokine receptors. In *Clinical Immunology*, 4th ed.; Rich, R.R., Fleisher, T.A., Shearer, W.T., Schroeder, H.W., Frew, A.J., Weyand, C.M., Eds.; Elsevier: London, UK, 2013; pp. 108–135.

144. Rose-John, S. Interleukin-6 Family Cytokines. *Cold Spring Harb. Perspect. Biol.* **2018**, *10*. [CrossRef]

145. Srinivasan, L.; Harris, M.C.; Kilpatrick, L.E. 128—Cytokines and Inflammatory Response in the Fetus and Neonate. In *Clinical Immunology*. 2nd ed.; Lorenzo, J., Horowitz, M.C., Choi, Y., Takayanagi, H., Schett, G., Eds.; Academic Press: San Diego, CA, USA, 2016; Chapter 9, pp. 143–167.

146. Giri, J.G.; Kumaki, S.; Ahdieh, M.; Friend, D.J.; Loomis, A.; Shanebeck, K.; DuBoise, R.; Cosman, D.; Park, L.S.; Anderson, D.M. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. *EMBO J.* **1995**, *14*, 3654–3663. [CrossRef]
150. Jin, W.; Dong, C. IL-17 cytokines in immunity and inflammation. *Emerg. Microbes Infect.* 2013, 2, e60. [CrossRef] [PubMed]

151. Tang, M.; Tian, L.; Luo, G.; Yu, X. Interferon-Gamma-Mediated Osteoimmunology. *Front. Immunol.* 2018, 9, 1508. [CrossRef] [PubMed]

152. Iguchi, M.; Hiroi, M.; Kanegae, H.; Ohmori, Y. Costimulation of Murine Osteoblasts with Interferon-γ and Tumor Necrosis Factor-α Induces Apoptosis through Downregulation of Bcl-2 and Release of Cytochrome c from Mitochondria. *Mediat. Inflamm.* 2018, 2018, 3979606. [CrossRef] [PubMed]

153. Damoulis, P.D.; Hauschka, P.V. Nitric Oxide Acts in Conjunction with Proinflammatory Cytokines to Promote Cell Death in Osteoblasts. *J. Bone Miner. Res.* 1997, 12, 412–422. [CrossRef] [PubMed]